Companies / Sagimet Biosciences Inc. / Activity
Activity — Sagimet Biosciences Inc.
23 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | Happel David CEO | Sell | Series A Common Stock | $64.9K | -12K -1.75% | 677,621 1.09% of shares | low |
| Feb 10, 2026 | Martins Eduardo Bruno Executive | Sell | Series A Common Stock | $19.5K | -4K -3.40% | 103,296 0.17% of shares | low |
| Feb 10, 2026 | Rozek Elizabeth Executive | Sell | Series A Common Stock | $14.1K | -3K -1.35% | 190,959 0.31% of shares | low |
| Feb 10, 2026 | Chauche Thierry Executive | Sell | Series A Common Stock | $7.0K | -1K -7.72% | 15,688 0.03% of shares | low |
| Feb 19, 2026 | Martins Eduardo Bruno Executive | Grant | Series A Common Stock | $0 | +44K +42.60% | 147,296 0.24% of shares | low |
| Feb 19, 2026 | Happel David CEO | Grant | Series A Common Stock | $0 | +128K +18.89% | 805,621 1.30% of shares | low |
| Feb 19, 2026 | Rozek Elizabeth Executive | Grant | Series A Common Stock | $0 | +44K +23.04% | 234,959 0.38% of shares | low |
| Feb 19, 2026 | Chauche Thierry Executive | Grant | Series A Common Stock | $0 | +44K +280.47% | 59,688 0.10% of shares | low |
| Jun 12, 2026 | Hoelscher Paul W. Director | Grant | Stock Option (Right to Buy) | — | +40K | 39,567 0.06% of shares | low |
| Jun 12, 2026 | Jarrett Jennifer Director | Grant | Stock Option (Right to Buy) | — | +40K | 39,567 0.06% of shares | low |
| Jun 12, 2026 | Kemble George Director | Grant | Stock Option (Right to Buy) | — | +40K | 39,567 0.06% of shares | low |
| Jun 12, 2026 | Phillips Anne M. Director | Grant | Stock Option (Right to Buy) | — | +40K | 39,567 0.06% of shares | low |
| May 28, 2026 | Chauche Thierry Executive | Grant | Stock Option (Right to Buy) | — | +50K | 50,000 0.08% of shares | low |
| May 28, 2026 | Grauer Andreas Executive | Grant | Stock Option (Right to Buy) | — | +35K | 35,000 0.06% of shares | low |
| May 28, 2026 | Rozek Elizabeth Executive | Grant | Stock Option (Right to Buy) | — | +100K | 100,000 0.16% of shares | low |
| May 28, 2026 | Happel David CEO | Grant | Stock Option (Right to Buy) | — | +300K | 300,000 0.48% of shares | low |
| Apr 20, 2026 | Grauer Andreas Executive | Grant | Stock Option (Right to Buy) | — | +265K | 264,759 0.43% of shares | low |
| Jun 12, 2026 | Grammer Elizabeth a Director | Grant | Stock Option (Right to Buy) | — | +40K | 39,567 0.06% of shares | low |
| Jun 12, 2026 | Seidenberg Beth C Director | Grant | Stock Option (Right to Buy) | — | +40K | 39,567 0.06% of shares | low |
| Feb 19, 2026 | Martins Eduardo Bruno Executive | Grant | Stock Option (Right to Buy) | — | +88K | 88,000 0.14% of shares | low |
| Feb 19, 2026 | Happel David CEO | Grant | Stock Option (Right to Buy) | — | +256K | 256,000 0.41% of shares | low |
| Feb 19, 2026 | Rozek Elizabeth Executive | Grant | Stock Option (Right to Buy) | — | +88K | 88,000 0.14% of shares | low |
| Feb 19, 2026 | Chauche Thierry Executive | Grant | Stock Option (Right to Buy) | — | +88K | 88,000 0.14% of shares | low |